Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Electrocore ( (ECOR) ) has shared an update.
On September 2, 2025, electroCore, Inc. appointed Elena Bonfiglioli as a new Class II member of its Board of Directors, expanding the Board from seven to eight members. Bonfiglioli, a seasoned healthcare executive with extensive experience at Microsoft, is expected to bring valuable insights into AI transformation and strategic partnerships in the health sector. Additionally, Thomas J. Errico, M.D., was appointed as the new chairman of the Board, succeeding F. Peter Cuneo following his retirement. The company’s annual meeting also included votes on several proposals, including the election of three Class I Directors and the ratification of CBIZ CPAs as the independent registered public accounting firm. However, a proposal to declassify the Board did not pass due to insufficient votes.
The most recent analyst rating on (ECOR) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Electrocore stock, see the ECOR Stock Forecast page.
Spark’s Take on ECOR Stock
According to Spark, TipRanks’ AI Analyst, ECOR is a Neutral.
Electrocore’s strong revenue growth is overshadowed by persistent profitability challenges and a weak technical outlook. The company’s strategic focus on growth may delay profitability, and the stock’s valuation is unattractive due to negative earnings. These factors contribute to a below-average overall stock score.
To see Spark’s full report on ECOR stock, click here.
More about Electrocore
electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies. The company’s leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, address chronic pain syndromes through non-invasive neuromodulation technology. Additionally, electroCore markets handheld and personal use products, Truvaga and TAC-STIM, utilizing bioelectronic technologies for general wellness and human performance.
Average Trading Volume: 102,908
Technical Sentiment Signal: Sell
Current Market Cap: $40.27M
Find detailed analytics on ECOR stock on TipRanks’ Stock Analysis page.